This content is only available within our institutional offering.
26 Jan 2026
Singer Capital Markets - Genus - Canada approves PRP
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Singer Capital Markets - Genus - Canada approves PRP
Genus plc (GNS:LON) | 3,032 606.5 0.7% | Mkt Cap: 2,018m
- Published:
26 Jan 2026 -
Author:
Edward Sham -
Pages:
3 -
Genus has taken another material step towards PRP commercialisation, with Canada approving use of Genus’s PRP gene edit, meaning it deems Genus’ gene-edited pork safe for sale and consumption. With the Canada approval secured, Mexico and Japan are the key approvals left before Genus can begin PRP commercialisation at scale.